Three new cases of ataxia-telangiectasia-like disorder: No impairment of the ATM pathway, but S-phase checkpoint defect.
Ataxia Telangiectasia
/ diagnosis
Ataxia Telangiectasia Mutated Proteins
/ genetics
Cell Line, Tumor
Child
Disease Susceptibility
Female
Gene Expression Profiling
Genetic Association Studies
Genetic Predisposition to Disease
Haplotypes
Humans
Infant
MRE11 Homologue Protein
/ genetics
Magnetic Resonance Imaging
Mutation
Phenotype
RNA Splicing
S Phase Cell Cycle Checkpoints
/ genetics
Signal Transduction
Transcriptome
MRN
ataxia
ataxia-telangiectasia mutated (ATM)
ataxia-telangiectasia-like disorder (ATLD)
checkpoint
meiotic recombination 11 (MRE11)
Journal
Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
07
09
2018
revised:
18
04
2019
accepted:
24
04
2019
pubmed:
30
4
2019
medline:
10
3
2020
entrez:
30
4
2019
Statut:
ppublish
Résumé
Ataxia-telangiectasia-like disorder (ATLD) is a rare genomic instability syndrome caused by biallelic variants of MRE11 (meiotic recombination 11) characterized by progressive cerebellar ataxia and typical karyotype abnormalities. These symptoms are common to those of ataxia-telangiectasia, which is consistent with the key role of MRE11 in ataxia-telangiectasia mutated (ATM) activation after DNA double-strand breaks. Three unrelated French patients were referred with ataxia. Only one had typical karyotype abnormalities. Unreported biallelic MRE11 variants were found in these three cases. Interestingly, one variant (c.424G>A) was present in two cases and haplotype analysis strongly suggested a French founder variant. Variants c.544G>A and c.314+4_314+7del lead to splice defects. The level of MRE11 in lymphoblastoid cell lines was consistently and dramatically reduced. Functional consequences were evaluated on activation of the ATM pathway via phosphorylation of ATM targets (KAP1 and CHK2), but no consistent defect was observed. However, an S-phase checkpoint activation defect after camptothecin was observed in these patients with ATLD. In conclusion, we report the first three French ATLD patients and a French founder variant, and propose an S-phase checkpoint activation study to evaluate the pathogenicity of MRE11 variants.
Substances chimiques
MRE11 protein, human
0
ATM protein, human
EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins
EC 2.7.11.1
MRE11 Homologue Protein
EC 3.1.-
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1690-1699Informations de copyright
© 2019 Wiley Periodicals, Inc.